Literature DB >> 16301272

Persistent cauda equina syndrome with no identifiable facilitating condition after an uneventful single spinal administration of 0.5% hyperbaric bupivacaine.

Thouraya Chabbouh1, Claude Lentschener, Mathieu Zuber, Nicole Jude, Bernard Delaitre, Yves Ozier.   

Abstract

We diagnosed cauda equina syndrome 15 h after uneventful single spinal administration of 0.5% hyperbaric bupivacaine 12.5 mg through a 27-gauge pencil-point type needle. No preexisting neurologic disorder was recorded. There was no pain or paresthesia during needle placement or drug injection. The sensory levels were bilateral, symmetric, and caudal to T8. Resolution of most of the symptoms occurred within a few days but some foot drop persisted for 2 yr after the procedure. Bupivacaine neurotoxicity is suggested by the absence of any other identifiable cause for this neurologic deficit.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301272     DOI: 10.1213/01.ANE.0000184126.57327.C3

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  4 in total

1.  Cauda equina syndrome following an uneventful spinal anaesthesia.

Authors:  Mamta Jain; Uma Srivastava; S Saxena; Anish K Singh; Aditya Kumar
Journal:  Indian J Anaesth       Date:  2010-01

2.  Vocal fold paralysis and cauda equina syndrome following spinal-epidural anesthesia: A case report.

Authors:  Yuanling Xiang; Weifeng Wang; Shenfeng Jing; Zhong Zhang; Dezhang Wang
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

3.  Unusual delayed presentation of cauda equina syndrome after failed spinal anesthesia.

Authors:  Kewal Krishan Gupta; Gurpreet Singh; Amanjot Singh; Mukesh Kumar
Journal:  Saudi J Anaesth       Date:  2015 Jul-Sep

4.  Acute cauda equina syndrome following orthopedic procedures as a result of epidural anesthesia.

Authors:  Lisa B E Shields; Vasudeva G Iyer; Yi Ping Zhang; Christopher B Shields
Journal:  Surg Neurol Int       Date:  2018-04-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.